Drug composition for angiogenesis therapy
OwnerTadashi Tanabe, Keiichi Hukuda +1inventors
InventorsTadashi Tanabe, Keiichi Hukuda, Takashi Kawakami
Life of this patent
Estimating the term…
Abstract
Drug compositions of angiogenesis therapy contain gene coding for human prostacyclin synthase (hPGIS) synthesizing prostaglandin I2 with activities of vasodialation and/or anti-platelet aggregation; drug compositions contain adeno-associated virus (AAV) inserted with gene for angiogenesis factors. The administration of the drug compositions into the aimed treatment region results in transfer of AAV type 1-hPGIS to skeletal muscles and induces a notable expression of human PGIS gene in skeletal muscles. The PGI2 is produced by mediation of the gene expression in the muscle cells, secreted, induces vessel-protective, neovascularization and anti-platelet aggregation actions, which lead to an improvement in vascular ischemia.
Claims6
A drug composition of angiogenesis therapy used for treatment and prevention of peripheral arterial disease comprising:
- an adeno-associated virus (AAV) inserted with a PGIS gene producing a prostaglandin I2 (PGI2) which induces the activities of vasodilation, anti-platelet aggregation, and angiogenesis, and further inserted with a gene coding for an angiogenesis factor,
- wherein PGI2 produced from the PGIS gene induces production of a vascular endothelial factor (VEGF).
A drug composition of angiogenesis therapy used for treatment and prevention of peripheral arterial disease comprising:
- a first adeno-associated virus (AAV) inserted with a PGIS gene producing a prostaglandin I2 (PGI2) which induces the activities of vasodilation, anti-platelet aggregation, and angiogenesis, wherein PGI2 produced from the PGIS gene induces production of a vascular endothelial factor (VEGF),
- and a second adeno-associated virus (AAV) inserted with a gene coding for an angiogenesis factor.
Dependencies are inferred from the claim text.